Develop Business Strategies Of The Trends Shaping And Driving Of Benign Prostatic Hyperplasia Therapeutics Market 2024

"The Latest Research Report OpportunityAnalyzer: Benign Prostatic Hyperplasia - Opportunity Analysis and Forecast to 2024 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

About Benign Prostatic Hyperplasia Market

GlobalData estimates the 2014 sales for the benign prostatic hyperplasia (BPH) therapeutics market at approximately $2 billion across the 7MM (US, Germany, France, Italy, Spain, UK and Japan). The US contributed a significant majority of these sales, generating an estimated $1.15 billion over the forecast period, ending in 2024. Benign Prostatic Hyperplasia therapeutics sales in the 7MM are expected to grow to $4.5 billion at a Compound Annual Growth Rate (CAGR) of 8.23%. The majority of sales in the 7MM in 2024 will come from the US, which will represent 65% of the market; with sales in the 5EU corresponding to 24%, while the remaining 12% in sales is attributable to Japan. The major driver for this growth across the 7MM will be the launch of NX-1207, a direct prostatic injection, which represents a first-in-class therapy for the treatment of moderate-to- severe BPH.

Highlights

Key Questions Answered

- Overall, the greatest unmet need in the BPH space is the issue with hard to treat symptoms such as nocturia and the presence of sexual adverse effects that are common with BPH medications. There are other prominent unmet needs highlighted by the Key Opinion Leaders (KOLs). What are these? Will the pipeline drugs fulfil these unmet needs of the market?
- The 10-year forecast period will mark the launch of three pipeline BPH drugs. How will the sales of the existing drugs be impacted? Which of the pipeline drugs will have the highest peak sales at the highest CAGR, and why?
- Four BPH therapies will face patent expiration during the forecast period resulting in a therapy area dominated by generics. How will this affect the market size? How will pharmaceutical companies be affected and how can they hope to profit in this environment?

Get Sample Copy of this report @ https://www.marketresearchreports.biz/sample/sample/491290

Key Findings

- The major driver for growth in the BPH market during the forecast period will be the launch of three pipeline therapies which each represent an improvement over currently available medications in their own right. KOLs believe that the launch of NX-1207, PRX302 and Vesomni will considerably change the treatment algorithm for patients with BPH.
- There are substantial unmet needs in the BPH area which need to be addressed. Targeting any of these unmet needs represents significant opportunities for investment in the area.
- KOLs believe that BPH is an underappreciated disease and that there is the potential for momentous growth in the field.

Scope

- Overview of BPH, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized BPH therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the BPH therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global BPH therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

View Report @ https://www.marketresearchreports.biz/reports/491290/opportunityanalyzer-benign-prostatic-hyperplasia-opportunity-analysis-and-forecast-to-2024-market-research-reports

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the BPH therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the BPH therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the 7MM BPH therapeutics market from 2014-2024.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents 8
1.1 List of Tables 12
1.2 List of Figures 14
2 Introduction 15
2.1 Catalyst 15
2.2 Related Reports 15
3 Disease Overview 16
3.1 Etiology and Pathophysiology 16
3.1.1 Etiology 16
3.1.2 Pathophysiology 20
3.2 Symptoms and Diagnosis 21
3.3 Quality of Life 25

Send An Enquiry Request @
https://www.marketresearchreports.biz/sample/enquiry/491290

4 Epidemiology 27
4.1 Disease Background 27
4.2 Risk Factors and Comorbidities 28
4.3 Global Trends 28
4.3.1 US 28
4.3.2 5EU 29
4.3.3 Japan 29
4.4 Forecast Methodology 29
4.4.1 Sources Used 30
4.4.2 Sources Not Used 31
4.4.3 Forecast Assumptions and Methods - Diagnosed Prevalent Cases 32
4.5 Epidemiological Forecast for BPH (2014-2024) 33
4.5.1 Diagnosed Prevalent Cases of BPH 33
4.5.2 Age-Specific Diagnosed Prevalent Cases of BPH 35
4.5.3 Diagnosed Prevalent Cases of BPH by Severity Using IPSS Criteria 36
4.5.4 Age Standardized Diagnosed Prevalence of BPH (%) 37
4.6 Discussion 38
4.6.1 Epidemiological Forecast Insight 38
4.6.2 Limitations of the Analysis 39
4.6.3 Strengths of the Analysis 39
5 Current Treatment Options 40
5.1 Overview 40
5.2 Product Profiles of Major BPH Brands 41
5.2.1 Flomax 41
5.2.2 Rapaflo 47
5.2.3 Uroxatral 53
5.2.4 Other 1-adrenoceptor antagonists 58
5.2.5 Finasteride 59
5.2.6 Avodart 66
5.2.7 Jalyn/Duodart 73
5.2.8 Cialis 79
5.2.9 Antimuscarinics 85
5.2.10 Phytotherapy 87
5.2.11 Medical Devices and Surgical Treatment 88
6 Unmet Needs Assessment and Oppportunity Analysis 90
6.1 Overview 90
6.2 There are No Effective Drugs for the Treatment of Nocturia 91
6.2.1 Unmet need 91
6.2.2 Gap Analysis 92
6.2.3 Opportunity 92
6.3 Sexual Adverse Effects Encountered Frequently in Patients Receiving BPH Medication 93
6.3.1 Unmet need 93
6.3.2 Gap Analysis 94
6.3.3 Opportunity 95
6.4 There is a Lack of Patient Awareness of BPH 95
6.4.1 Unmet Need 95
6.4.2 Gap Analysis 96
6.4.3 Opportunity 97
6.5 There are No Accurate Techniques for the Early Detection of BPH 97
6.5.1 Unmet Need 97
6.5.2 Gap Analysis 98
6.5.3 Opportunity 98
6.6 There are No Drugs that Target the Cause of BPH 99
6.6.1 Unmet Need 99
6.6.2 Gap Analysis 100
6.6.3 Opportunity 100
6.7 Physician Education about BPH is Poor 100
6.7.1 Unmet Need 100
6.7.2 Gap Analysis 101
6.7.3 Opportunity 102

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz

This release was published on openPR.